Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Eur J Hosp Pharm

	Drop out patients (n=16)	Patients ending the study (n=73)	p-value (t student or χ^2)
Age (yr)	62.4 ± 6.8	60.0 ± 3.0	0.532 [a]
Body mass index (kg/m²)	28.2 ± 1.9	27.6 ± 1.2	0.619 [a]
Number of men (n)	7 (43.8%)	48 (65.7%)	0.100 [b]
Social level (n)			
1	9 (56.3%)	24 (32.9%)	
2	2 (12.5%)	16 (21.9%)	0.211 [b]
3	5 (31.3%)	33 (45.2%)	
Kidney failure (n)	2 (12.5%)	12 (16.4%)	NA
Liver failure (n)	0 (0.0%)	1 (1.4%)	*NA*
Number of total chronic disease (n)			
1	2 (12.5%)	17 (23.3%)	
2	7 (43.8%)	19 (26.0%)	0.324 [b]
>2	7 (43.8%)	37 (50.7%)	
Number of diseases involved in the study (n)			
1	13 (81.3%)	60 (82.2%)	0.929 [b]
Hypertension	6 (37.5%)	40 (54.8%)	
Type 2 diabetes	5 (31.3%)	10 (13.7%)	0.202 [b]
Hypercholesterolemia	2 (12.5%)	10 (13.7%)	
2	3 (18.8%)	12 (16.4%)	0.823 [b]
Hypertension + Type 2 diabetes	3 (18.8%)	9 (12.3%)	0.386 [b]
Hypertension + Hypercholesterolemia	0 (0.0%)	1 (1.4%)	*NA*
Type 2 diabetes + Hypercholesterolemia	0 (0.0%)	2 (2.8%)	*NA*
3	0 (0.0%)	1 (1.4%)	*NA*
Number of different drugs prescribed	5.6 ± 1.5	5.6 ± 0.8	0.992 [a]
Adjusted number of different drugs prescribed (n)			
<5	7 (43.8%)	29 (39.7%)	0.766 [b]
≥5	9 (56.3%)	44 (60.3%)	

1

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Eur J Hosp Pharm

Side effects at the inclusion (n)	5 (31.3%)	15 (20.5%)	0.352 [b]
Adherence score at the inclusion	1.8 ± 0.6	2.1 ± 0.3	0.348 [a]
Patient with hypertension (n)	9 (56.3%)	51 (69.9%)	0.292 [b]
used as primary outcome	7 (43.8%)	49 (67.1%)	0.080 [b]
Patient with type II diabetes (n)	5 (31.3%)	22 (30.1%)	0.930 [b]
used as primary outcome	5 (31.3%)	11 (15.0%)	0.127 [b]
Patient with hypercholesterolemia (n)	5 (31.3%)	14 (19.2%)	0.286 [b]
used as primary outcome	4 (25%)	13 (17.8%)	0.507 [b]

Supplemental Table 1: characteristics at baseline of drop out and patients ending the study. Data are expressed as proportion of patients and in number of patients for qualitative variables, and as mean ± 95% confidence interval for quantitative variables. [a]student t test. [b]chi square test.